The Novacyt share price has 20-bagged in 2020. Is there still time to buy?

The Novacyt share price is flying as sales of Covid-19 tests soar. Alan Oscroft asks if the share price represents good long-term value.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Covid-19 pandemic has wrought havoc in the stock market, and most UK shares have tumbled in price. But some, like Novacyt (LSE: NCYT) have done just the opposite. The Novacyt share price today stands more than 20 times higher than it was at the beginning of the year.

It has been a lot higher, though. I’ve you were lucky enough to sell at the peak in mid-April, you could have pocketed a 38-bagger. Those who bought at the peak are now 40% down on their investment. Growth share prices often fall back a bit from their early peaks due to profit-taking before continuing up. So is the current dip a buying opportunity?

The soaring ride of the Novacyt share price has all been down to demand for its Covid-19 tests. On Tuesday, the company gave us an updateon its polymerase chain reaction (PCR) test for COVID-19, developed by Primerdesign, the Company’s molecular diagnostics division“.

Sales are booming in 2020

By 1 June, sales of the test had reached €45m (£40m), with orders and contracts for delivery adding a further €90m (£80m). That takes total sales and confirmed orders to €135m (£120m). Considering that the firm’s consolidated revenue for the whole of 2019 came to £11.5m, the reason for the huge surge in the Novacyt share price is clear.

Although 2019 brought home only modest adjusted EBITDA of €0.2m, the company was making steady progress. The year was the company’s third consecutive one with positive EBITDA. And Novacyt suggested it could have been better had it not faced working capital constraints. Well, with the cash that’s rolling in this year, I think working capital constraints should be a thing of the past.

Does the Novacyt share price reflect the long term?

Though Novacyt is looking a lot more like a viable prospect now, there’s a big question in my mind. Does the Novacyt share price genuinely reflect the company’s long-term prospects? Let’s look further at the latest update. The Primerdesign test is now being sold in more than 130 countries, and the UK and Germany are the biggest customers. Entry into the US market seems uncertain at this point, but the firm says it is “pleased with the progress it is making“.

The French government has not approved the test, which is a bit of a setback, and the Novacyt share price fell on the news. As I write, it’s 7% down on the day.

Sales could keep on soaring

This is generally all very impressive, but I see one huge potential downside. Sales of Novacyt’s coronavirus test could well explode in the coming months, as countries move from lockdown to mass testing. But how many tests will Novacyt sell next year? In 2022 and beyond?

If someone develops an effective vaccine, that number could plunge to zero. And if that happens, the Novacyt share price will need to be valued on the rest of the company’s products.

I see Novacyt as a potentially great long-term investment, and the company should certainly get an enormous boost from its Covid-19 test. But I’ll wait and see what the Novacyt share price looks like when the pandemic is behind us.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »